Lumos Diagnostics (ASX:LDX)
ASX announcement history & article coverage
Transparent by design.
Announcments by Lumos Diagnostics (ASX:LDX) are listed here, whether we covered it or not. Where we've written an article, you'll see it linked directly. Where we haven't, the filing is still shown so nothing is hidden from view. If you think a particular announcement deserved editorial coverage and was overlooked, you can flag it for review and our team will take a look.
Application for quotation of securities - LDX
Q1 FY27 Quarterly Results Date & Webinar Invitation
Final Director's Interest Notice - LM
Initial Director's Interest Notice - AS
Notice of Annual General Meeting and Proxy Form
Lumos Diagnostics Board Changes
Notification of cessation of securities - LDX
Section 708A Cleansing Statement
Application for quotation of securities - LDX
Change in substantial holding from RYD
Section 708A Cleansing Statement
Application for quotation of securities - LDX
FebriDx Commercial Traction Continues Across US Accounts
Lumos expands FebriDx U.S. rollout to 215 live sites as top health-system accounts advance
Section 708A Cleansing Statement
Application for quotation of securities - LDX
Change of Director's Interest Notice - DW
Appendix 4G and Corporate Governance Statement
FY26 Full Year Results Announcement
Lumos secures US$317m PHASE deal, FDA CLIA waiver, Medicare coverage; FY26 revenue up 6%
FY26 Annual Report
Lumos Diagnostics achieves FDA CLIA waiver for FebriDx®, secures US$317 million distribution deal, reports revenue growth and reduced loss in FY26
FY26 Appendix 4E
Lumos Diagnostics reports revenue growth and reduced loss for FY2026 with going concern uncertainty noted
Lumos to Present at 20th Bioshares Biotech Summit
Lumos Receives FebriDx Order from PHASE Scientific
Lumos Diagnostics secures US$767,800 FebriDx order from PHASE Scientific following FDA CLIA waiver
Lumos Secures Distribution for FebriDx in Romania
Change of Director's Interest Notice - DW
Section 708A Cleansing Statement
Application for quotation of securities - LDX
Investor Presentation
Quarterly Activities/Appendix 4C Cash Flow Report
Lumos Diagnostics FY26 Revenue Up 6% Driven by FebriDx® Growth and CLIA Waiver Milestones
FebriDx Commercial Traction Across Priority US Accounts
Lumos advances FebriDx rollout in top U.S. urgent care groups with network expansion underway
